e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Clinical implications of asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characterisation of a cohort of asthmatics with severe concordant eosinophilic disease according to their IgE status
S. Gerday (Liege, Belgium), F. Schleich (Liege, Belgium), M. Henket (Liege, Belgium), F. Guissard (Liege, Belgium), V. Paulus (Liege, Belgium), R. Louis (Liege, Belgium)
Source:
International Congress 2019 – Clinical implications of asthma management
Session:
Clinical implications of asthma management
Session type:
Poster Discussion
Number:
5028
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Gerday (Liege, Belgium), F. Schleich (Liege, Belgium), M. Henket (Liege, Belgium), F. Guissard (Liege, Belgium), V. Paulus (Liege, Belgium), R. Louis (Liege, Belgium). Characterisation of a cohort of asthmatics with severe concordant eosinophilic disease according to their IgE status. 5028
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Transcriptomic profiles of eosinophilic asthmatic patients classified according to their atopic status
Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough
Year: 2021
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Distribution of the cellular inflammatory pattern in induced sputum in an eosinophilic severe asthma population.
Source: International Congress 2019 – Airway diseases and blood cells
Year: 2019
Clinical profile of patients with adult-onset eosinophilic asthma
Source: ERJ Open Res 2016: 00100-2015
Year: 2016
Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD
Source: Eur Respir J, 50 (5) 1701162; 10.1183/13993003.01162-2017
Year: 2017
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study.
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Cellular inflammatory pattern in induced sputum among patients with stable moderate or severe asthma
Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases
Year: 2010
Specific features of phenotypes of polymorphic haptoglobin system in patients with chronic bronchitis and healthy smokers
Source: Eur Respir J 2001; 18: Suppl. 33, 24s
Year: 2001
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Serial blood eosinophils and clinical characteristics in COPD patients without a history of asthma or atopy
Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Year: 2019
Associations between inflammatory endotypes and phenotypes of obesity at young patients with bronchial asthma
Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities
Year: 2020
Airway eosinophilia is not related to clinical and functional findings in a large group of severe refractory asthmatics
Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers
vs
induced sputum
Year: 2006
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma
Source: Eur Respir J 2003; 22: 470-477
Year: 2003
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021
Predictors of methacholine responsiveness in a population of patients with suspected bronchial asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 295s
Year: 2003
Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
The effects of IL12B promoter polymorphism on co-existence of allergic rhinitis or familial asthma history, serum total IgE and eosinophil level in asthma patients
Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Year: 2008
Incidence of allergic asthma in patients with sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 232s
Year: 2006
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept